Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

NCT06025227 | Unknown

• 1 other identifier: C504
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.

Conditions

Colitis, Ulcerative

Keywords

Ulcerative Colitis

Interventions

Etrasimod DRUG

tablets

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

Patient must be intolerant, have a contraindication or had inadequate response to at least 3 therapies available for Ulcerative Colitis (UC) in this country or provide a rationale of why therapy was not used.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Pfizer: lead

MeSH Terms

Conditions

Colitis, Ulcerative

Interventions

etrasimod

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Central Study Contacts

PfizerCares

CONTACT

PfizerCares@Pfizer.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 29, 2023
• First Posted: September 6, 2023
• Last Updated: November 18, 2025

Record last verified: 2025-11